Early Returns

New Years always brings out the prognosticator in all of us. Everyone likes to predict what the market will do, what sectors will shine and their favorite stock for the coming 52 weeks. I'm no different, having given out...
Tailwinds' Take: this is outstanding news. Once again the science at HJLI is showing a dramatic divergence from the crazy-low valuation. After their funding issues are behind them, we expect to see the stock trading at a significantly higher...
In December of 2019, INmune Bio (INMB) commenced dosing of humans in a Phase 1b trial of XPro1595 (XPro), a drug targeting Alzheimer’s Disease. This trial is an 18 patient trial that is designed to run for 12 weeks...
What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us small cap investors, it was particularly painful. There seemed to be zero bids out there...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because of it?), led by a 22% gain in Provention Bio, we managed to put up...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.